Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond
- 2 November 2012
- journal article
- review article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 47 (2), 121-141
- https://doi.org/10.1177/0004867412461958
Abstract
Background: Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder associated with a significant degree of functional disability and poor quality of life. Pharmacotherapy may have a substantial impact on the course and outcome of OCD. Method: We review the evidence supporting available strategies for the pharmacological treatment of OCD. Results: Selective serotonin reuptake inhibitors (SSRIs) remain the pharmacological treatment of choice and are associated with improved health-related quality of life. Discontinuation is associated with relapse and loss of quality of life, implying treatment should continue long-term. A substantial minority of patients who fail to respond to SSRI may benefit from dose elevation or adjunctive antipsychotics, though long-term trials validating the effectiveness and tolerability of these strategies are relatively lacking. Conclusion: The pharmacological evidence-base for the treatment of OCD is becoming increasingly robust. Treatment with SSRIs and clomipramine remains uncontroversial and improvements are sustained over time. Newer compounds targeting serotonin receptor subtypes and other neurotransmitter systems are undergoing evaluation.Keywords
This publication has 98 references indexed in Scilit:
- A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive DisorderBiological Psychiatry, 2010
- Predictors and Moderators of Treatment Outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I)Journal of the American Academy of Child & Adolescent Psychiatry, 2010
- A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorderHuman Psychopharmacology: Clinical and Experimental, 2010
- Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive DisorderJournal of Child and Adolescent Psychopharmacology, 2010
- Probing Compulsive and Impulsive Behaviors, from Animal Models to Endophenotypes: A Narrative ReviewNeuropsychopharmacology, 2009
- Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorderMolecular Psychiatry, 2009
- 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorderEuropean Neuropsychopharmacology, 2008
- Obsessive-compulsive severity spectrum in the community: prevalence, comorbidity, and courseArchiv Fur Psychiatrie Und Nervenkrankheiten, 2004
- A Controlled Trial of Lithium Augmentation in Fluvoxamine-Refractory Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 1991
- Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosisProgress in Neuro-Psychopharmacology, 1981